Cargando…

Gene-Based Therapeutics for Parkinson’s Disease

Parkinson’s disease (PD) is a complex multifactorial disorder that is not yet fully surmised, and it is only when such a disease is tackled on multiple levels simultaneously that we should expect to see fruitful results. Gene therapy is a modern medical practice that theoretically and, so far, pract...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shalaby, Karim E., El-Agnaf, Omar M. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331241/ https://www.ncbi.nlm.nih.gov/pubmed/35892690 http://dx.doi.org/10.3390/biomedicines10081790

Ejemplares similares

Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors
por: Shalaby, Karim, et al.
Publicado: (2020)

Rapid Assessment of CRISPR Transfection Efficiency and Enrichment of CRISPR Induced Mutations Using a Dual-Fluorescent Stable Reporter System
por: Shalaby, Karim E., et al.
Publicado: (2022)

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage
por: Majbour, Nour, et al.
Publicado: (2022)

Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson’s disease in rodent brains
por: Bérard, Morgan, et al.
Publicado: (2023)

Decrease in Plasma Levels of α-Synuclein Is Evident in Patients with Parkinson’s Disease after Elimination of Heterophilic Antibody Interference
por: Ishii, Ryotaro, et al.
Publicado: (2015)

Diagnostic, Prognostic, and Mechanistic Biomarkers of Diabetes Mellitus-Associated Cognitive Decline
por: Ehtewish, Hanan, et al.
Publicado: (2022)

Paving the Way toward Personalized Medicine: Current Advances and Challenges in Multi-OMICS Approach in Autism Spectrum Disorder for Biomarkers Discovery and Patient Stratification
por: Mesleh, Areej G., et al.
Publicado: (2021)

Gene Therapeutic Approaches for the Treatment of Mitochondrial Dysfunction in Parkinson’s Disease
por: Prasuhn, Jannik, et al.
Publicado: (2021)

Correlated levels of cerebrospinal fluid pathogenic proteins in drug-naïve Parkinson’s disease
por: Murakami, Hidetomo, et al.
Publicado: (2019)

Therapeutic Strategies for Immune Transformation in Parkinson’s Disease
por: Saleh, Maamoon, et al.
Publicado: (2022)

Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
por: Oliveira, Luis M. A., et al.
Publicado: (2021)

The therapeutic role of minocycline in Parkinson’s disease
por: Cankaya, Seyda, et al.
Publicado: (2019)

The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson’s Disease
por: Titze-de-Almeida, Simoneide S., et al.
Publicado: (2020)

Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease
por: Hoekstra, Jake G, et al.
Publicado: (2011)

Norepinephrine: the next therapeutics frontier for Parkinson's disease
por: LeWitt, Peter A
Publicado: (2012)

Emerging Role of Plant-Based Bioactive Compounds as Therapeutics in Parkinson’s Disease
por: Kumari, Nitu, et al.
Publicado: (2023)

Therapeutic potential of autophagy-enhancing agents in Parkinson’s disease
por: Moors, Tim E., et al.
Publicado: (2017)

Therapeutic targeting of mitophagy in Parkinson's disease
por: Masaldan, Shashank, et al.
Publicado: (2022)

Mitochondria: A Therapeutic Target for Parkinson’s Disease?
por: Luo, Yu, et al.
Publicado: (2015)

Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
por: Pajares, Marta, et al.
Publicado: (2020)

Genotype-driven therapeutic developments in Parkinson’s disease
por: Prasuhn, Jannik, et al.
Publicado: (2021)

Ceramide Metabolism and Parkinson’s Disease—Therapeutic Targets
por: Custodia, Antía, et al.
Publicado: (2021)

Role of Deubiquitinases in Parkinson’s Disease—Therapeutic Perspectives
por: Nielsen, Pernille Y. Ø., et al.
Publicado: (2023)

New Avenues for Parkinson’s Disease Therapeutics: Disease-Modifying Strategies Based on the Gut Microbiota
por: Lorente-Picón, Marina, et al.
Publicado: (2021)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

The Epigenome as a therapeutic target for Parkinson's disease
por: Hegarty, Shane V., et al.
Publicado: (2016)

Gastrointestinal Dysfunction in Parkinson’s Disease: Current and Potential Therapeutics
por: Han, Myat Noe, et al.
Publicado: (2022)

The recommendations of Chinese Parkinson’s disease and movement disorder society consensus on therapeutic management of Parkinson’s disease
por: Chen, Shengdi, et al.
Publicado: (2016)

c-Abl and Parkinson’s Disease: Mechanisms and Therapeutic Potential
por: Brahmachari, Saurav, et al.
Publicado: (2017)

Neuropeptide S Receptor as an Innovative Therapeutic Target for Parkinson Disease
por: Holanda, Victor A. D., et al.
Publicado: (2021)

Gene and Cell-Based Therapies for Parkinson’s Disease: Where Are We?
por: Buttery, Philip C., et al.
Publicado: (2020)

Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human α-synuclein in transgenic mouse brain
por: Cronin, Kenneth D., et al.
Publicado: (2009)

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
por: Majbour, Nour K., et al.
Publicado: (2016)

Early-onset parkinsonism in a pedigree with phosphoglycerate kinase deficiency and a heterozygous carrier: do PGK-1 mutations contribute to vulnerability to parkinsonism?
por: Sakaue, Satoshi, et al.
Publicado: (2017)

Cerebrospinal Fluid Lysosomal Enzymes and Alpha-Synuclein in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

Neuroinflammation and Parkinson’s Disease—From Neurodegeneration to Therapeutic Opportunities
por: Araújo, Bruna, et al.
Publicado: (2022)

Are heat shock proteins therapeutic target for Parkinson's disease?
por: Luo, Guang-Rui, et al.
Publicado: (2006)

Mechanisms and therapeutic applications of electromagnetic therapy in Parkinson’s disease
por: Vadalà, Maria, et al.
Publicado: (2015)

Neuroinflammation in Parkinson’s disease and its potential as therapeutic target
por: Wang, Qinqin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_44s2qj57nenud2jf50p9qlm1gf